GLYCOPEPTIDE ANTIBIOTICS MARKET ANALYSIS

Glycopeptide antibiotics are actinomycete-derived antibiotics with unique tricyclic or tetracyclic heptapeptide cores that are usually glycosylated and sometimes have additional lipophilic fatty acid side chains.

Global Glycopeptide Antibiotics market is estimated to be valued at US$  2,860.5 million in 2022 and is expected to exhibit a CAGR of 4.2% during the forecast period (2022-2030).

Figure 1. Global Glycopeptide Antibiotics Market Share (%) in Terms of Value, By Region, 2022

To learn more about this report, request sample copy

Global Glycopeptide Antibiotics Market - Drivers

The increasing cases of cancer and infectious diseases such as  enterococcal infections, Hepatitis and others is expected to drive the market growth during the forecast period. For instance, according to data published in September 2022 by the Centers for Disease Control and Prevention (CDC), the number of tuberculosis cases in the year 2019 in the U.S. was 8,916.

Increasing product approvals for the treatment of infectious diseases are expected to drive the market growth during the forecast period. For instance, in July 2021, AbbVie Inc., a U.S. biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) had approved DALVANCE for the treatment of acute bacterial skin and skin structure infections (ABSSSI).

Figure 2. Global Glycopeptide Antibiotics Market Share (%), By Distribution Channel, 2022

To learn more about this report, request sample copy

Global Glycopeptide Antibiotics Market – Impact of Coronavirus (COVID-19) Pandemic

The COVID-19 pandemic significantly impacted the glycopeptide antibiotics market. This included disruption in clinical trials, hurdles in patient recruitment for clinical trials, and canceled or delayed studies. However, the negative impact was gradually reduced by several strategic measures taken by governments, regulatory bodies, and market stakeholders to ensure the continuity of research and development (R&D) activities. Due to the urgent need for vaccines, diagnostics, and therapies, the clinical trials were restarted by employing social distancing techniques. Moreover, to support the clinical trials of COVID-19 vaccines and treatments, public organizations across the globe invested in research and development activities. For instance, according to an article published in BMJ Publishing Group Ltd., a U.K.-based publisher of medical journals, since January 2020, the U.K. government was found to be the largest funder of Oxford–AstraZeneca vaccine R&D, contributing £33,354,469 (US$ 36,762,962) (95.5%). Charitable funders accounted for £1,217,835 (US$ 1,342,286) (3.5%), the majority of which came from the Welcome Trust. Globally, most sites conducting clinical trials other than COVID-19 were found to experience delays in timelines. In some cases, clinical trials were found to reach a complete halt of operations, thus impacting clinical research outcomes. In March 2020, the U.S. FDA published a guidance document on the Conduct of Clinical Trials of Medical Products during the pandemic. Similar guidelines supported the recovery of the clinical trial operations and the number is expected to increase over time.

Global Glycopeptide Antibiotics Market: Restraint

The major factors that hinder growth of the global glycopeptide antibiotics market include increase in glycopeptide antibiotic resistance cases. For instance, according to Antibiotic Resistance Threats Report in the United States, 2019, Enterococcus which is Vancomycin (glycopeptide antibiotic) resistant bacteria caused 5,400 deaths in U.S. in 2019.

Global Glycopeptide Antibiotics Market: Key Players

Key players operating in the market include ANI Pharmaceuticals, Inc., Fresenius SE & Co. KGaA, Pfizer Inc., Mylan N.V., Novartis AG, Hikma Pharmaceuticals plc, Aurobindo Pharma, AbbVie Inc., Melinta Therapeutics, Inc, Cumberland Pharmaceuticals Inc., Theravance Biopharma, Janssen Global Services, LLC, Bristol-Myers Squibb Company, and GlaxoSmithKline plc.